October 2, 2020
October 2, 2020 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab) used in
combination with Yervoy® (ipilimumab) to provide first-line treatment of adults
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
October 2, 2020
October 2, 2020 – Teva Pharmaceuticals has announced the launch of generics for Gilead’s Truvada
(emtricitabine/tenofovir disoproxil fumarate) and Atripla (efavirenz/
September 30, 2020
September 30, 2020 – The U.S. FDA has approved a new indication for Simponi Aria® (golimumab),
manufactured by Janssen Pharmaceutical, to treat active polyarticular
September 30, 2020
September 30, 2020 – The U.S. FDA has approved Alkindi® Sprinkle (hydrocortisone) oral granules,
manufactured by Eton Pharmaceutical, to provide replacement therapy for
September 30, 2020
September 30, 2020 – Lupin Pharmaceuticals has announced the launch of its generic version of Novartis’s
Tykerb® (lapatinib) 250mg tablets. Lapatinib is indicated for the
September 28, 2020
September 28, 2020 – The U.S. FDA has approved an expanded indication for Kalydeco® (ivacaftor),
manufactured by Vertex Pharmaceuticals. The drug is now indicated to treat
September 28, 2020
September 28, 2020 – The U.S. FDA has approved an expanded indication for Haegarda® [C1 esterase
inhibitor (human)], manufactured by CSL Behring. The drug is now indicated
September 28, 2020
September 28, 2020 – The U.S. FDA has approved a new indication for Xeljanz® (tofacitinib), manufactured by Pfizer, to treat patients who are at least two years old and have active